Takeda Pharmaceutical launched on December 3 a new 25 mg version of its DPP-4 inhibitor Zafatek Tablets (trelagliptin), making it possible for the drug to be used in patients with severe renal impairment or patients on dialysis with end-stage renal…
To read the full story
Related Article
- Evenity Ordered to Warn of CV Event Risks in Revised Label
September 9, 2019
BUSINESS
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





